References
- Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X, Xie D. Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium. Eur Arch Otorhinolaryngol 2014;271:265–73.
- Caliman e Gurgel JD, Pereira SB, Alves AL, Alves AL, Ribeiro FQ. Hyperproliferation markers in ear canal epidermis. Braz J Otorhinolaryngol 2010;76:667–71.
- Xie S, Xiang Y, Wang X, Ren H, Yin T, Ren J, Liu W. Acquired cholesteatoma epithelial hyperproliferation: roles of cell proliferation signal pathways. Laryngoscope 2016;126:1923–30.
- Thorup MV, Munk M, Poulsen SS, Gaihede M, Nexo E, Sorensen BS, Ovesen T. Expression of the epidermal growth factor system in human middle ear cholesteatoma. Acta Otolaryngol 2014;134:124–34.
- Liu W, Ren H, Ren J, Yin T, Hu B, Xie S, et al. The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma. Mediators Inflamm 2013;2013:651207.
- Tang XH, Deng S, Li M, Lu MS. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer. Biochem Biophys Res Commun 2012;422:676–80.
- Sato K, Takaishi M, Tokuoka S, Sano S. Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model. PLoS One 2014;9:e112408.
- Morita S, Shirakata Y, Shiraishi A, Kadota Y, Hashimoto K, Higashiyama S, Ohashi Y. Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members. Mol Vis 2007;13:2119–28.
- Suzukawa K, Tomlin J, Pak K, Chavez E, Kurabi A, Baird A, Wasserman SI, Ryan AF. A mouse model of otitis media identifies HB-EGF as a mediator of inflammation-induced mucosal proliferation. PLoS One 2014;9:e102739.
- Kuczkowski J, Sakowicz-Burkiewicz M, Iżycka-Świeszewska E. Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. Am J Otolaryngol 2010;31:404–9.
- Jin K, Mao XO, Sun Y, Xie L, Jin L, Nishi E, Klagsbrun M, Greenberg DA. Heparin-binding epidermal growth factor-like growth factor: hypoxia-inducible expression in vitro and stimulation of neurogenesis in vitro and in vivo. J Neurosci 2002;22:5365–73.
- Iwamoto R, Takagi M, Akatsuka J, Ono K, Kishi Y, Mekada E. Characterization of a novel anti-human HB-EGF monoclonal antibody applicable for paraffin-embedded tissues and diagnosis of HB-EGF-related cancers. Monoclon Antib Immunodiagn Immunother 2016;35:73–82.
- Yang CC, Tu HF, Wu CH, Chang HC, Chiang WF, Shih NC, et al. Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC. Oral Oncol 2016;56:54–61.
- Chung HW, Kong HY, Lim JB. Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer. World J Gastroenterol 2015;21:2080–8.
- Bourgeois DL, Kabarowski KA, Porubsky VL, Kreeger PK. High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation. Cancer Cell Int 2015;15:112.
- Luo S, Liu X, Zheng Y, Xu W, Ni H, Li Y, Liu Q. Interleukin-22 upregulates HB-EGF expression in HaCaT cells via JAK2/STAT3 and ERK1/2 signalling. Exp Dermatol 2015;24:713–4.
- Yoshida A, Kanno H, Watabe D, Akasaka T, Sawai T. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha. Arch Dermatol Res 2008;300:37–45.
- Long DL, Ulici V, Chubinskaya S, Loeser RF. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is increased in osteoarthritis and regulates chondrocyte catabolic and anabolic activities. Osteoarthrit Cartilage 2015;23:1523–31.
- Maniu A, Harabaqiu O, Perde Schrepler M, Cătană A, Fănuţă B, Mogoantă CA. Molecular biology of cholesteatoma. Rom J Morphol Embryol 2014;55:7–13.
- Nam SO, Yotsumoto F, Miyata K, Souzaki R, Taguchi T, Kuroki M, Miyamoto S. Validity of HB-EGF as target for human neuroblastoma therapy. Anticancer Res 2015;35:4433–40.